scholarly journals Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

2019 ◽  
Vol 9 (4) ◽  
Author(s):  
Suzanne Trudel ◽  
Nikoletta Lendvai ◽  
Rakesh Popat ◽  
Peter M. Voorhees ◽  
Brandi Reeves ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase I ◽  
Phase I Study ◽  
Antibody Drug Conjugate ◽  
Expansion Phase ◽  
Safety And Efficacy ◽  
Refractory Multiple Myeloma ◽  
Drug Conjugate ◽  
Antibody Drug

scholarly journals Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

2019 ◽  
Vol 9 (2) ◽  
Author(s):  
A. Keith Stewart ◽  
Amrita Y. Krishnan ◽  
Seema Singhal ◽  
Ralph V. Boccia ◽  
Manish R. Patel ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase I ◽  
Phase I Study ◽  
Antibody Drug Conjugate ◽  
Refractory Multiple Myeloma ◽  
Drug Conjugate ◽  
Antibody Drug

scholarly journals First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

2020 ◽  
Vol 26 (10) ◽  
pp. 2308-2317 ◽  
Author(s):  
Ravi Vij ◽  
Rajneesh Nath ◽  
Daniel E.H. Afar ◽  
María-Victoria Mateos ◽  
Jesús G. Berdeja ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase I ◽  
Phase I Study ◽  
Antibody Drug Conjugate ◽  
Refractory Multiple Myeloma ◽  
Drug Conjugate ◽  
Antibody Drug

A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 2511-2511 ◽  
Author(s):  
Carlos Alberto Gomez-Roca ◽  
Valentina Boni ◽  
Victor Moreno ◽  
John Charles Morris ◽  
Jean-Pierre Delord ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Advanced Solid Tumors ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document